Zantac Back On Shelves
The FDA has approved a reformulated version of ranitidine (Zantac), more than 5 years after requesting the antacid be pulled from shelves over concerns that it could break down into a carcinogen. As Dr. Melillo explained, After ranitidine was removed from the market, Zantac rebranded themselves to Zantac 360, but the ingredient is different.
The reformulated Zantac 360 contains famotidine, the generic version of Pepcid, another H2 receptor antagonist that was not affected by NDMA concerns. Ranitidine products, including Zantac, were pulled from shelves in April 2020 after regulators determined the impurity could increase to unsafe levels over time, particularly when stored at... The U.S.
Food and Drug Administration has requested a manufacturers market withdrawal of ranitidine, known commonly by the brand name Zantac. In 2020, original Zantac was recalled over cancer concerns. Is Zantac back on the shelf? Yes, but as Zantac 360, a different medication with famotidine.
That withdrawal remains in effect, and no traditional ranitidine product has returned to pharmacy shelves. If youve seen Zantac at the store recently, youre looking at a completely different medication. Ranitidine is back on the US market after a five-year absence.
The FDA has approved a reformulated version of the drug, once known as Zantac, following major manufacturing changes and new safety testing. In 2020, the FDA requested the immediate withdrawal of all prescription and over-the-counter (OTC) ranitidine drugs (commonly known as brand name Zantac) from the market due to concerns about an N-nitrosodimethylamine (NDMA) impurity formation during the products shelf-life. Zantac is back with new formulations approved by the FDA after safety reviews and stricter storage guidelines.
Learn more now. Discover if Zantac is back! Explore FDA regulations, safe alternatives, and legal actions in a comprehensive guide.
